ibandronic acid has been researched along with Prostatic Neoplasms in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 15 (65.22) | 29.6817 |
| 2010's | 5 (21.74) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Hua, Q; Li, H; Wang, L; Xu, T | 1 |
| Achel, DG; Alcaraz, M; Alcaraz-Saura, M; Olivares, A | 1 |
| Brown, J; Fullarton, JR; Palmieri, C | 1 |
| Felsenberg, D; Gabbert, TI; Hoffmeister, B | 1 |
| Bloomfield, D; Forsyth, S; Hackshaw, A; Hoskin, P; Jitlal, M; Kirkwood, A; Mithal, N; Reczko, K; Sizer, B; Stratford, M; Sundar, S; Upadhyay, S; Wilson, P | 1 |
| Joensuu, TK | 1 |
| Colombel, M | 1 |
| Aragon-Ching, JB; Arlen, PM; Chen, CC; Dahut, WL; Figg, WD; Guadagnini, JP; Gulley, JL; Latham, L; Ning, YM; Parnes, H; Wright, JJ | 1 |
| Jeremiah, S; Morgan, C; Wagstaff, J | 1 |
| Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K | 1 |
| Morgan, C; Wagstaff, J | 1 |
| Engelmann, U; Epplen, R; Heidenreich, A; Ohlmann, CH; Stöckle, M | 1 |
| Elert, A; Heidenreich, A; Hofmann, R | 1 |
| Heidenreich, A | 1 |
| Rexer, H | 1 |
| Bell, R; Coleman, R; Heidenreich, A | 1 |
| Allhoff, EP; Lindenmeir, T; Rau, O; Reiher, F; Ulrich, M | 1 |
| McKeage, K; Plosker, GL | 1 |
| Boissier, S; Clezardin, P; Cuzin, B; Delmas, PD; Ebetino, FH; Frappart, L; Magnetto, S | 1 |
| Black, C; Coleman, RE; Huss, H; Kanis, J; Purohit, OP; Quinn, KJ; Schlosser, K; Vinholes, JJ | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O | 1 |
| Oppenkowski, R; Seegenschmiedt, MH | 1 |
6 review(s) available for ibandronic acid and Prostatic Neoplasms
| Article | Year |
|---|---|
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Neoplasm Metastasis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid | 2013 |
Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases?
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Male; Prostatic Neoplasms; Treatment Outcome | 2009 |
Bisphosphonates in the management of metastatic prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Male; Pain; Palliative Care; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2003 |
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Quality-Adjusted Life Years; Zoledronic Acid | 2008 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
[Radiotherapy and bisphosphonate therapy in bone metastases of prostate carcinoma].
Topics: Bone Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Diphosphonates; Humans; Ibandronic Acid; Male; Neoplasm Staging; Palliative Care; Prostatic Neoplasms; Radiotherapy; Survival Rate | 2001 |
3 trial(s) available for ibandronic acid and Prostatic Neoplasms
| Article | Year |
|---|---|
A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Infusions, Intravenous; Male; Middle Aged; Pain; Palliative Care; Prostatic Neoplasms; Quality of Life; Radiotherapy Dosage; Time Factors; Treatment Outcome | 2015 |
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
Topics: Adult; Aged; Alendronate; Angiogenesis Inhibitors; Diphosphonates; Humans; Ibandronic Acid; Incidence; Jaw Diseases; Male; Middle Aged; Neoplasm Metastasis; Osteonecrosis; Prostatic Neoplasms | 2009 |
Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Area Under Curve; Biomarkers; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ibandronic Acid; Male; Middle Aged; Multiple Myeloma; Prognosis; Prospective Studies; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 1999 |
14 other study(ies) available for ibandronic acid and Prostatic Neoplasms
| Article | Year |
|---|---|
177Lu-DOTA-IBA Therapy in Prostate Cancer With Bone Metastases.
Topics: Bone Neoplasms; Humans; Ibandronic Acid; Male; Prostatic Neoplasms; Radiopharmaceuticals | 2023 |
Effects of bisphosphonates in combination with ionizing radiation and antioxidants on the growth of prostate and melanoma cells lines.
Topics: Animals; Antioxidants; Apigenin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Melanoma; Mice; Pamidronate; Prostatic Neoplasms; Radiation, Ionizing; Skin Neoplasms; Zoledronic Acid | 2013 |
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid | 2015 |
Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Bone Neoplasms; Creatinine; Diphosphonates; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Male; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Retreatment; Risk Assessment; Treatment Outcome; Zoledronic Acid | 2008 |
[Prescription of bisphosphonates in prostate cancer].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Humans; Ibandronic Acid; Imidazoles; Injections; Male; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Zoledronic Acid | 2008 |
Ibandronate reduces endogenous reactive oxygen species levels in cultured prostate cancer and endothelial cells.
Topics: Bone Density Conservation Agents; Cell Line, Tumor; Cells, Cultured; Diphosphonates; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Fluoresceins; Fluorescent Dyes; Humans; Ibandronic Acid; Male; Oxidation-Reduction; Prostatic Neoplasms; Reactive Oxygen Species; Time Factors; Umbilical Veins | 2009 |
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Greece; Humans; Ibandronic Acid; Imidazoles; Incidence; Jaw Diseases; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2009 |
Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Diphosphonates; Docetaxel; Drug Synergism; Farnesol; Humans; Ibandronic Acid; Male; Mevalonic Acid; Prenylation; Prostatic Neoplasms; Signal Transduction; Taxoids | 2011 |
Ibandronate in the treatment of prostate cancer associated painful osseous metastases.
Topics: Aged; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Male; Middle Aged; Pain; Prospective Studies; Prostatic Neoplasms | 2002 |
[Therapy of painful bone metastases in patients with prostate carcinoma. The AP 32/02 Study of the AUO].
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Male; Mitoxantrone; Pain; Patient Selection; Prednisolone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2004 |
Managing metastatic bone disease: three case studies.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Kidney Neoplasms; Male; Neoplasms, Second Primary; Palliative Care; Prostatic Neoplasms | 2004 |
[Adjuvant therapy of locally advanced prostate carcinoma with ibandronate].
Topics: Biomarkers, Tumor; Bone Density Conservation Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Diphosphonates; Drug Administration Schedule; Humans; Ibandronic Acid; Infusions, Intravenous; Long-Term Care; Male; Neoplasm Invasiveness; Neoplasm Staging; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms | 2007 |
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.
Topics: Bone Matrix; Bone Neoplasms; Breast Neoplasms; Calcification, Physiologic; Cell Adhesion; Cell Adhesion Molecules; Clodronic Acid; Diphosphonates; Extracellular Matrix; Female; Humans; Ibandronic Acid; In Vitro Techniques; Integrins; Male; Neoplasm Metastasis; Osteoblasts; Pamidronate; Prostatic Neoplasms; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured | 1997 |
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2000 |